Medical Review Disclosure
This content has been reviewed for medical accuracy. Always consult a qualified healthcare professional before making any medical decisions. [Last reviewed: 2026-06-10]
Cancer treatment has undergone dramatic shifts in the last ten years. For many decades now, surgery, radiation, and chemotherapy have been the major modes of cancer treatment.
While all three methods remain important for the cure of cancer, an emerging treatment called immunotherapy is revolutionizing the oncology treatment modality.
Immunotherapy works differently from traditional cancer therapies because it does not rely on chemicals used to directly target cancerous tissues.
Rather, the approach involves activation of the patient's own immune system. Amongst the key drugs that form the basis of this revolutionary new medical practice is Pembrolizumab, commonly referred to as Keytruda.
Pembrolizumab is a monoclonal antibody that belongs to the humanized, biological IgG4 kappa isotype class of drugs. It was produced by Merck Sharp & Dohme and gained FDA approval as an oncology treatment in 2014.
How Pembrolizumab Works: Unmasking Cancer Cells
To understand how Pembrolizumab works, it helps to look at how cancer interacts with the immune system.
The PD-1/PD-L1 Pathway: The Biological "Brake"
The body's immunity uses certain types of specialized cells known as T-cells (or white blood cells) that help recognize and destroy foreign cells such as viruses or bacteria.
The body employs an interesting tactic of employing "immune checkpoints" to protect the body from its own defenses.
A common "checkpoint" is that of programmed cell death protein 1, or PD-1. When healthy cells use PD-L1 or PD-L2 as their markers, they bind with the PD-1 receptor of the T-cell, thereby sending an "off switch" command that acts as a brake to its operations.
However, some tumors can actually utilize this mechanism against the immune system. The tumor produces a huge amount of PD-L1, causing the tumor cells to bind with the T-cells, rendering them harmless by protecting the cells from apoptosis.
Restoring Immune Surveillance
Pembrolizumab is considered an immune checkpoint inhibitor because its mechanism of action operates just like a lock-and-key system, where it perfectly locks the PD-1 receptors on T cells.
Binding to PD-1 receptors enables pembrolizumab to block any ligand interaction between PD-1 and either PD-L1 or PD-L2.
Without the ability to communicate its "shut-off" message, the cancer cell cannot inhibit the immune response against the tumors; rather, T-cell activation ensues with the help of the patient's immune system.
Approved Clinical Uses: Where is it Prescribed?
Pembrolizumab is highly versatile. It can be prescribed as a monotherapy (a single agent) or as part of a combination chemotherapy regimen.
Doctors deploy it across various FDA-approved indications, depending on a patient's cancer stage and specific genetic markers.
Pembrolizumab is extremely versatile in its use as either a monotherapy or combination therapy.
Physicians can administer this drug for any of the FDA-approved uses for different patients who suffer from different stages of cancer based on certain gene types.
Key Indications
- Advanced Melanoma: It may be applied as a first-line therapy for metastatic melanoma (a type of skin cancer that has metastasized) or as adjuvant therapy (prevention therapy following surgery) for Stage IIB, IIC, or III melanomas.
- Non-Small Cell Lung Cancer (NSCLC): One of the major applications of the drug is Non-Small Cell Lung Cancer. The drug will be recommended when the tumor shows high expression of the PD-L1 protein (TPS of ≥ 1%) without certain genetic alterations, including EGFR mutation and ALK translocation.
- Solid Tumors Driven by Biomarkers: Pembrolizumab became famous due to "tissue-agnostic" approval. This means that the drug can be used against any solid tumors at different locations within the body provided that those tumors show particular genetic alterations including MSI-H, dMMR markers, and TMB-H.
- Other Major Cancers: It is used in treating Triple-Negative Breast Cancer (TNBC), Urothelial Carcinoma (bladder cancer), Classical Hodgkin Lymphoma (cHL), and advanced Head and Neck Squamous Cell Carcinoma (HNSCC).
Quick Reference: Biomarkers and Settings
Cancer Type & Indication | Key Biomarker / Clinical Requirement | Standard Clinical Setting |
Advanced Melanoma | Unresectable or metastatic; Stage IIB, IIC, or III | Monotherapy (First-line or Adjuvant post-surgery) |
Non-Small Cell Lung Cancer (NSCLC) | PD-L1 Expression (TPS ≥ 1%) | Monotherapy or combined with platinum chemotherapy |
MSI-H / dMMR Solid Tumors | Microsatellite Instability-High / Mismatch Repair Deficient | Systemic therapy after progression on prior treatments |
Triple-Negative Breast Cancer (TNBC) | High-risk early-stage OR tumor expressing PD-L1 (CPS ≥ 10) | Combined with chemotherapy (neoadjuvant or adjuvant) |
Classical Hodgkin Lymphoma (cHL) | Relapsed or refractory disease | Monotherapy for pediatric and adult patients |
Administration, Dosage, and Pharmacokinetics
Pembrolizumab cannot be taken as a pill. It is manufactured as either a 50 mg lyophilized powder or a 25 mg/mL liquid solution, which is diluted for clinical use.
Method of Delivery
In order to avoid dosage mistakes and wastage, doses for adults are not based on their weight. They are set in fixed doses, with two such schedules being available for use with sufficient therapeutic coverage:
Standard Fixed-Dosing Schedules
The medication is characterized by an incredibly high terminal half-life that equals 26-27 days. Because of this, its effects can be felt in the body for quite some time, which is why doses can be given 3 to 6 times monthly.
- 200 mg every 3 weeks, OR
- 400 mg every 6 weeks
Pharmacokinetic Profile
Pembrolizumab has a very long elimination terminal half-life of approximately 26 to 27 days.
This means it stays active in the body for a long time, which is why treatments can safely be spaced out every 3 to 6 weeks.
Side Effect Profiles and Safety Information
While Pembrolizumab does not typically cause traditional chemotherapy side effects like severe hair loss, it does possess a unique safety profile.
Common Adverse Events
Most patients tolerate the medication well. The most frequent mild side effects include:
- Chronic fatigue and tiredness
- Musculoskeletal or joint pain
- Mild nausea and decreased appetite
- Skin rash and itchy skin (pruritus)
- Mild diarrhea or cough
Serious Immune-Mediated Adverse Reactions (irAEs)
Since Pembrolizumab blocks the natural brake on the immune system, there may be some cases when the highly active T-cells mistakenly attack the healthy organs of the body, which need immediate medical treatment:
- Immune-mediated pneumonitis: An inflammatory lung condition, presenting with symptoms of shortness of breath, chest pain, or coughing.
- Colitis: Severe intestinal inflammation, which may cause severe diarrhea and abdominal pain.
- Hepatitis: Inflammation of the liver, seen through signs of yellowish skin and high liver enzymes.
- Endocrinopathies: Conditions like thyroiditis, adrenal insufficiency, or hypophysitis, which affect the production of hormones in the body.
- Nephritis: Abnormal kidney function causing changes in urine output or high creatinine levels.
Adverse Event Management
It is not advised to prescribe Pembrolizumab to pregnant females since it can lead to severe injuries of a fetus.
Therefore, all female patients should use reliable contraceptives during their therapy and for 4 months after their last medication intake. Moreover, lactation is not recommended during this period.
Special Precautions
It is not advised to prescribe Pembrolizumab to pregnant females since it can lead to severe injuries of a fetus.
Therefore, all female patients should use reliable contraceptives during their therapy and for 4 months after their last medication intake. Moreover, lactation is not recommended during this period.
Real-World Applications & Patient Experience
There exists one special phenomenon that pharmacists and clinicians observe during the use of Pembrolizumab in practice.
At first stages of medication, patients' scans may show an increase in the size of their tumors. Actually, this is caused by the activation of immune cells that were brought by the drug into a microenvironment near tumors.
In order to provide maximum safety for patients and to properly monitor them, a team of healthcare specialists such as oncologists, pharmacists, and nurses is needed.
Conclusion: The Future of Immunotherapy
Pembrolizumab has changed cancer management and is listed by the World Health Organization as one of its “Essential Medicines.”
By allowing the body to eliminate cancer cells in a natural way, it has increased the chances of survival for millions of people.
Trials are still underway regarding its effects in the early stages of cancer and how it can work synergistically with other biological treatments.
Frequently Asked Questions (FAQ)
1. Does Pembrolizumab cure cancer?
While it is a highly effective treatment that can shrink tumors and significantly prolong life, it is generally referred to as a long-term control therapy for advanced stages rather than a definitive "cure."
2. How long do patients stay on Pembrolizumab treatment?
For most advanced cancers, patients continue treatment as long as the drug is working and side effects remain manageable, typically up to a maximum of 24 months (2 years).
3. Can I get vaccines while receiving Keytruda?
You should consult your oncologist before receiving any vaccine. Generally, live vaccines are avoided during immunotherapy because your immune system is being actively altered by the medication.
References & Trusted Sources
- National Center for Biotechnology Information (NCBI) StatPearls: Pembrolizumab Profile
- DrugBank Online: Pembrolizumab (DB09037) Technical Data
- Official Manufacturer Site: Keytruda (Pembrolizumab) Patient & Clinician Portals
- Cancer Research UK: Pembrolizumab Cancer Treatment Guide
- ScienceDirect Topics: Pembrolizumab Applications in Medicine and Dentistry
Related: View all cancer medicine medications